UBS raised its price target on Biogen (NASDAQ: BIIB) to $285.00 (from $270.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Biogen (BIIB) PT Raised to $328 at BMO Capital; '2Q17 Couldn’t Have Been Better Operationally'July 26, 2017 10:53 AM Biogen (BIIB) PT Raised to $311 at Morgan StanleyJuly 26, 2017 7:58 AM Biogen (BIIB) PT Raised to $319 at Deutsche BankJuly 26, 2017 6:24 AM Goldman Sachs Upgrades Biogen (BIIB) to BuyJuly 26, 2017 5:07 AM Biogen (BIIB) Said Contacted by Prosecution Office of MilanJuly 25, 2017 5:13 PM Pre-Open Movers 07/25: (BKS) (COT) (CAT) Higher; (STX) (NVAX) (GOOGL) Lower (more...)July 25, 2017 9:30 AM Biogen (BIIB) CEO says 'we will explore deals of all sizes' - BloombergJuly 25, 2017 8:54 AM Ionis (IONS) Partner Biogen Reports Blow-Out Spinraza Sales - BMO CapitalJuly 25, 2017 7:50 AM Biogen (BIIB) Tops Q2 EPS by 59c, Sales Beat; Raises OutlookJuly 25, 2017 6:31 AM Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue GuidanceJuly 25, 2017 6:30 AM Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic OperationsJuly 24, 2017 4:15 PM Biogen (BIIB) weekly volatility increases into Q2 and outlookJuly 24, 2017 6:24 AM